Efficacy and Safety in Patients (Pts) with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up

Kanter, Julie; Thompson, Alexis A.; Kwiatkowski, Janet L.; Parikh, Suhag; Mapara, Markus Y.; Rifkin-Zenenberg, Stacey; Aygün, Banu; Kasow, Kimberly A.; Gupta, Ashish O.; Zhang, Lixin

doi:10.1016/j.jtct.2023.12.302

Efficacy and Safety in Patients (Pts) with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up

NobleIDNI9P04W21R03S47

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/ECCCC201.svg?ark=w1%2F20260521%2FECCCC201&value=id)](https://nobleid.org/work/w1/20260521/ECCCC201)

ARK Inflections

Metadata (JSON)Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Stacey Rifkin-Zenenberg

Claim authorship of this work

Efficacy and Safety in Patients (Pts) with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up

NobleIDNI9P04W21R03S47

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/ECCCC201.svg?ark=w1%2F20260521%2FECCCC201&value=id)](https://nobleid.org/work/w1/20260521/ECCCC201)

ARK Inflections

Metadata (JSON)Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Stacey Rifkin-Zenenberg

Claim authorship of this work